

Supplemental Table 1 Comparison of changes in serum creatinine and estimated glomerular filtration rate between the tenofovir amibufenamide and tenofovir alafenamide groups in patients with cirrhosis

	TMF group (<i>n</i> = 23)	TAF group (<i>n</i> = 19)	P value
Creatinine (μmol/L)			
Before treatment	89.00 (76.95,93.50)	79.80 (73.50,89.60)	0.412
After 48 wk	78.00 (65.20,89.70)	80.35 (63.80,91.03)	0.961
Reduction	4.00 (-13.25,9.18)	-4.50 (-8.00,3.50)	0.255
<i>P</i> (baseline <i>vs.</i> 48 wk)	0.228	0.770	
eGFR (mL/min/1.73 m ²)			
Before treatment	92.80 (89.15,101.02)	95.30 (87.95,100.65)	0.339
After 48 wk	102.80 (86.60,106.37)	105.02 (90.31,137.83)	0.232
Reduction	-5.60 (-26.21,2.00)	-5.37 (-38.19,0.43)	0.901
<i>P</i> (baseline <i>vs.</i> 48 wk)	0.801	0.129	

Data are median M (P25, P75). TMF: Tenofovir amibufenamide; TAF: Tenofovir alafenamide; eGFR: Estimated glomerular filtration rate.

Supplemental Table 2 Comparison of changes in liver stiffness measurement and fibrosis 4 score between the tenofovir amibufenamide and tenofovir alafenamide groups in patients with cirrhosis

	TMF group (<i>n</i> = 23)	TAF group (<i>n</i> = 19)	<i>P</i> value
LSM (Kpa)			
Before treatment	15.55(10.78,20.05)	13.90(12.48,14.80)	0.198
After 48 wk	14.60(9.70,15.00)	10.95(10.10,12.55)	0.142
Reduction	0.70(-0.17,5.88)	0.75(-0.25,5.32)	0.792
<i>P</i> (baseline vs. 48 wk)	0.523	0.124	
FIB-4			
Before treatment	3.05(1.84,7.29)	2.74(1.40,3.99)	0.463
After 48 wk	4.49(2.32,6.83)	2.55(1.70,4.68)	0.025
Reduction	0.29(0.06,0.77)	-0.43(1.16, -0.08)	0.001
<i>P</i> (baseline vs. 48 wk)	0.582	0.785	

Data are median M (P25, P75). TMF: Tenofovir amibufenamide; TAF: Tenofovir alafenamide; LSM: Liver stiffness measurement (FibroScan); FIB-4: Fibrosis 4 score.